Heart failure has gained increasing notice due to its high prevalence and mortality rate. The management for heart failure has been emphasized on the role of device therapy. Implantable cardioverter defibrillator(ICD)...Heart failure has gained increasing notice due to its high prevalence and mortality rate. The management for heart failure has been emphasized on the role of device therapy. Implantable cardioverter defibrillator(ICD) and cardiac resynchronization therapy(CRT) were given strong recommendation for heart failure with reduced ejection fraction(HFrEF), considering their effectiveness on preventing sudden cardiac death(SCD), improving cardiac function and benefiting survival. In this review, we explained the underlying mechanisms of disease initiation and progression in HFrEF, in order to build the connection between the pathological basis of HFrEF and the rationality of ICD and CRT on terminating ventricular arrhythmia, improving cardiac function, decreasing the rate of adverse clinical outcomes and benefiting survival. In addition, we discussed the high-quality researches with significant values on the discovery of device therapy clinical benefits, and compared the class I recommendations for device therapy in HFr EF, suggested by American Heart Association and European Society of Cardiology.展开更多
Background Diastolic heart failure（DHF）, also known as heart failure with preserved ejection fraction（HFpEF）, is a common clinical phenomenon that has reached 50% of heart failure（HF）. It has high morbidity and ...Background Diastolic heart failure（DHF）, also known as heart failure with preserved ejection fraction（HFpEF）, is a common clinical phenomenon that has reached 50% of heart failure（HF）. It has high morbidity and mortality and seriously affects the quality of life in the elders. Over the past decade, many studies on the pathogenesis, diagnosis, and treatments of DHF have been reported. In this article, we summarized the latest research to provide a theoretical basis for better management of DHF.展开更多
基金supported by grants from Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention (No. Y0120220151)Science and Technology Projects of Guangzhou (No. 201903010097)+1 种基金National Natural Science Foundation of China (No. 82002014)Natural Science Foundation of Guangdong Province (No. 2021A1515010107)。
文摘Heart failure has gained increasing notice due to its high prevalence and mortality rate. The management for heart failure has been emphasized on the role of device therapy. Implantable cardioverter defibrillator(ICD) and cardiac resynchronization therapy(CRT) were given strong recommendation for heart failure with reduced ejection fraction(HFrEF), considering their effectiveness on preventing sudden cardiac death(SCD), improving cardiac function and benefiting survival. In this review, we explained the underlying mechanisms of disease initiation and progression in HFrEF, in order to build the connection between the pathological basis of HFrEF and the rationality of ICD and CRT on terminating ventricular arrhythmia, improving cardiac function, decreasing the rate of adverse clinical outcomes and benefiting survival. In addition, we discussed the high-quality researches with significant values on the discovery of device therapy clinical benefits, and compared the class I recommendations for device therapy in HFr EF, suggested by American Heart Association and European Society of Cardiology.
文摘Background Diastolic heart failure（DHF）, also known as heart failure with preserved ejection fraction（HFpEF）, is a common clinical phenomenon that has reached 50% of heart failure（HF）. It has high morbidity and mortality and seriously affects the quality of life in the elders. Over the past decade, many studies on the pathogenesis, diagnosis, and treatments of DHF have been reported. In this article, we summarized the latest research to provide a theoretical basis for better management of DHF.
